Do I need a COVID-19 booster shot?
THE increasing prevalence of new coronavirus variants is raising questions about how well protected those who've already had their COVID-19 shots are against evolving forms of the SARS-CoV-2 virus. Here, microbiology and infectious disease specialist William Petri of the University of Virginia answers some common questions about COVID-19 booster shots. 1. Boosters are an extra dose of a vaccine given to maintain vaccine-induced protection against a disease. They are commonly used to bolster many vaccines because immunity can wear off over time. For example, the flu vaccine needs a booster every year, and the diphtheria and tetanus vaccine every 10 years. Boosters are often identical to the original vaccine. In some cases, however, the booster shot has been modified to enhance protection against new viral variants. The seasonal flu vaccine, most notably, requires an annual booster because the flu virus changes so rapidly. 2. Not yet. As of early July 2021, none of the US Government authorities is recommending a booster. This includes the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA) and the Advisory Committee on Immunization Practices to the CDC. 3. While vaccine-induced immunity may not last forever, it is not clear when a booster will be needed. Encouragingly, all of the currently authorised COVID-19 vaccines induce a robust immune memory against the novel coronavirus. The vaccine teaches your immune system's memory B cells to produce antibodies when you're exposed to the virus. Researchers have detected high levels of memory B cells in the lymph nodes of people who received the Pfizer vaccine for at least 12 weeks after they got the shot. Studies also suggest that authorised COVID-19 vaccines are continuing to offer protection even against emerging strains of the novel coronavirus. Among one study's participants, the Johnson & Johnson vaccine had 73 per cent and 82 per cent efficacy 14 days and 28 days post-shot, respectively, at warding off severe disease from the beta variant. And a preliminary study that has not been peer-reviewed found the Pfizer vaccine to be 88 per cent effective against the Delta variant. The other source of long-lasting antibody responses against the coronavirus is cells called plasmablasts that reside in bone marrow. These cells continuously produce antibodies and do not require boosting to maintain their activity. Fortunately, plasmablasts have been detected in the bone marrow of people who received the COVID-19 vaccine for up to 11 months, indicating some degree of long-lasting immune memory. 4. You may need to wait for an outbreak in people who have been vaccinated. Researchers are still figuring out the best way to measure the strength of someone's vaccine-induced immunity. The COVID-19 vaccines have been so effective that there are not many failures to test. The best candidate to measure are certain antibodies the vaccine induces the immune system to make. They recognise the spike protein that allows the coronavirus to enter and infect cells. Evidence supporting the importance of anti-spike antibodies includes a study showing that the somewhat more effective mRNA vaccines like Pfizer and Moderna generate higher antibody levels in the blood than the adenovirus vector vaccines like Johnson & Johnson and AstraZeneca. In a preliminary study that has not yet been peer-reviewed, anti-spike antibody levels were lower in people who caught COVID-19 after they were vaccinated with the OxfordAstraZeneca vaccine. Medical workers would love to be able to give patients a blood test that would tell them how well protected they are or aren't against COVID-19. That would be a clear indication as to whether a booster shot is needed. But, until researchers know for sure how to measure vaccine-induced immunity, the next indication that boosters may be needed are breakthrough infections in older adults who have already been vaccinated. People over the age of 80 make lower levels of antibodies after vaccination, so their immunity may wane sooner than that of the general population. The elderly would also most likely be the most susceptible to new viral variants that evade the protection current vaccines provide. 5. I'm immunocompromised. Boosters may be necessary for immunocompromised people. In one study, 39 of 40 kidney transplant recipients and a third of dialysis patients failed to make antibodies after vaccination. Another study identified 20 patients with rheumatic or musculoskeletal diseases on medications that suppress the immune system who also did not have detectable antibodies. Both of these studies were done after patients received the full vaccine dose. Boosters have been shown to help in these cases. In one study, one-third of solid organ transplant patients who had a suboptimal response to two doses of the Pfizer or Moderna vaccines were able to develop an antibody response with a third dose. Those who are immunocompromised may wonder if the vaccine they received is successfully generating immunity in their body. A preliminary study, that has not yet been peer-reviewed, did find that a test that specifically targets the anti-spike antibodies the vaccines trigger may be helpful in determining whether the vaccine worked. But for now, the FDA does not recommend antibody tests to assess immunity. 6. Likely not. Recent research has shown that mRNA vaccines, like Pfizer and Moderna, can be mixed with adenovirus-based vaccines like AstraZeneca with comparable results. Taken from the Associated Press, this article was originally published on The Conversation , an independent and non-profit source of news, analysis and commentary from academic experts.